Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Medincell's annualizedGross Profit for the quarter that ended in Mar. 2026 was $18.29 Mil.
Medincell's average Total Assets over the quarter that ended in Mar. 2026 was $106.22 Mil. Therefore, Medincell's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2026 was 17.22%.
Medincell Gross-Profit-to-Asset % Related Terms
Medincell Gross-Profit-to-Asset % Historical Data
* Premium members only.
The historical data trend for Medincell's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Gross-Profit-to-Asset % Comparison
For the Biotechnology subindustry, Medincell's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Gross-Profit-to-Asset % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Medincell's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is two times the semi-annual (Mar. 2026) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
What does a Gross-Profit-to-Asset % of 17.22% mean?
Medincell (MDCLF) has a Gross-Profit-to-Asset % of 17.22% as of Mar. 2026. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Medincell and its competitors. According to the industry distribution chart, Medincell ranks #296 out of 955 companies in the Biotechnology industry, placing it in the top 31%.
Is Medincell's Gross-Profit-to-Asset % too high?
Medincell's current Gross-Profit-to-Asset % is 17.22%. The Biotechnology industry median Gross-Profit-to-Asset % is 11.11. Medincell's value of 17.22% is 55% above this industry median. Based on the distribution chart, Medincell ranks #296 out of 955 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Gross-Profit-to-Asset % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #296 out of 955 companies for Gross-Profit-to-Asset %. This puts Medincell in the upper half of its industry. The industry median Gross-Profit-to-Asset % is 11.11. Medincell's value of 17.22% is 55% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross-Profit-to-Asset % for a Biotechnology company?
The median Gross-Profit-to-Asset % among Biotechnology companies is 11.11, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Gross-Profit-to-Asset % significantly above this median, while those in the bottom quartile fall well below. However, Gross-Profit-to-Asset % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Gross-Profit-to-Asset % of 17.22% is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross-Profit-to-Asset % mean?
A high Gross-Profit-to-Asset % can signal that a stock is expensive relative to its fundamentals. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Gross-Profit-to-Asset % is 11.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Gross-Profit-to-Asset % is 17.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Gross-Profit-to-Asset % of 17.22%. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Gross-Profit-to-Asset % is 17.22% and 55% above the Biotechnology industry median of 11.11. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross-Profit-to-Asset % calculated?
Gross-Profit-to-Asset % is calculated from a company's financial statements. For Medincell (MDCLF), the current Gross-Profit-to-Asset % is 17.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Gross-Profit-to-Asset %: 17.22%
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 55% above the Biotechnology median (#296 of 955)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Gross-Profit-to-Asset % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
